Melatonin influences pancreatic cancerogenesis

Area of Science:

• Endocrinology
• Oncology
• Immunology

Background:

• Pancreatic cancer has a poor prognosis due to late diagnosis and treatment resistance.
• Melatonin, an indoleamine, is present in the pancreas and may influence cancer development.
• Oxidative stress and inflammation are implicated in pancreatic oncogenesis.

Purpose of the Study:

• To explore the potential role of melatonin in modulating pancreatic cancer progression.
• To investigate melatonin's effects on oxidative stress, apoptosis, angiogenesis, and immune response in pancreatic cancer.
• To assess melatonin's impact on chemotherapy efficacy and side effects in preclinical models.

Main Methods:

• Review of existing evidence on melatonin's biological activities relevant to pancreatic cancer.
• Analysis of melatonin's effects on antioxidant pathways, apoptosis signaling (Bax/Bcl, caspases), and heat shock proteins in pancreatic cancer cells.
• Evaluation of melatonin's impact on angiogenesis (VEGF) and immune cells (T cells).
• Examination of preclinical animal studies on melatonin's effects on chemotherapy.

Main Results:

• Melatonin acts as an antioxidant, protecting pancreatic tissue from oxidative and inflammatory damage.
• High melatonin doses induce apoptosis in pancreatic cancer cells via the mitochondrial pathway, while low doses promote survival.
• Melatonin inhibits angiogenesis by reducing vascular endothelial growth factor (VEGF) and strengthens immune defense.
• Animal studies indicate melatonin can enhance chemotherapy efficacy and reduce its side effects.

Conclusions:

• Melatonin exhibits multifaceted anti-cancer properties relevant to pancreatic cancer.
• High-dose melatonin shows potential as a supportive therapy for pancreatic cancer.
• Further research is needed to clarify melatonin's precise role in apoptosis regulation within pancreatic cancer treatment.